Bexarotene-Induced Hypertriglyceridemia: A Case Report

We present a case of a patient with cutaneous T-cell lymphoma started on bexarotene 300 mg/m² due to progressing disease. The patient experienced good clinical response, but unfortunately, she developed rapid and profound hypertriglyceridemia. Although hypertriglyceridemia occurs in high incidence with bexarotene therapy, management recommendations are scarce. Due to the rise in triglycerides, atorvastatin 10 mg daily was initiated in combination with fenofibrate 120 mg daily. Triglycerides continued to increase, so the patient was instructed to take atorvastatin 40 mg, fenofibrate 120 mg, and to hold bexarotene for 2 weeks. After the 2-week break, bexarotene was restarted at 150 mg/m².
Case Rep Oncol 2018;11:234–238

https://ift.tt/2JDJr9i